

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC2/21 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 14.09.2021

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

## Test

Sample	Group		N	Result	N <sub>rel</sub>
<b>(601) A1 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	>>>	7	Negative (0)	15 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	12	Negative (0)	25 %
		>	2	Negative (1+)	4,2 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	23	Negative (0)	48 %
	(999) another manufacturer	>>>	4	Negative (0)	8,3 %
Total per sample: n = 48			Success: 100 %		
Total success: 100 %					
<b>(602) A2 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	>>>	7	Strong positive (3+)	15 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	14	Strong positive (3+)	29 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	23	Strong positive (3+)	48 %
	(999) another manufacturer	>	2	Weak positive (2+)	4,2 %
		>>>	2	Strong positive (3+)	4,2 %
Total per sample: n = 48			Success: 100 %		
Total success: 100 %					
<b>(603) A3 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	>>>	6	Negative (0)	13 %
		>	1	Negative (1+)	2,1 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	9	Negative (0)	19 %
		>	5	Negative (1+)	10 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	23	Negative (0)	48 %
	(999) another manufacturer	>>>	3	Negative (0)	6,3 %
		>	1	Negative (1+)	2,1 %
Total per sample: n = 48			Success: 100 %		
Total success: 100 %					
<b>(606) B1 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	±	1	Negative (1+)	2,1 %
		±	6	Weak positive (2+)	13 %
	(803) Dako c-erbB-2 Onkoprotein	±	1	Negative (0)	2,1 %
		±	5	Negative (1+)	10 %
		±	8	Weak positive (2+)	17 %
	(804) Ventana PATHWAY anti-HER-2/neu	±	1	Negative (0)	2,1 %
		±	19	Negative (1+)	40 %
		±	3	Weak positive (2+)	6,3 %
	(999) another manufacturer	±	3	Negative (1+)	6,3 %
		±	1	Weak positive (2+)	2,1 %
Total per sample: n = 48			Success (only evaluated results): evaluation		
<b>(607) B2 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	>>>	7	Negative (1+)	15 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	4	Negative (0)	8,3 %
		>>>	7	Negative (1+)	15 %
			3	Weak positive (2+)	6,3 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	10	Negative (0)	21 %
		>>>	12	Negative (1+)	25 %
			1	Weak positive (2+)	2,1 %
	(999) another manufacturer	>>>	2	Negative (0)	4,2 %
		>>>	2	Negative (1+)	4,2 %
Total per sample: n = 48			Success: 92 %		
Total success: 92 %					
<b>(608) B3 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	±	2	Negative (1+)	4,2 %
		±	5	Weak positive (2+)	10 %
	(803) Dako c-erbB-2 Onkoprotein	±	4	Negative (1+)	8,3 %
		±	10	Weak positive (2+)	21 %
	(804) Ventana PATHWAY anti-HER-2/neu	±	7	Negative (1+)	15 %
		±	16	Weak positive (2+)	33 %
	(999) another manufacturer	±	1	Negative (0)	2,1 %
		±	1	Negative (1+)	2,1 %
		±	2	Weak positive (2+)	4,2 %
Total per sample: n = 48			Success (only evaluated results): evaluation		
<b>(611) C1 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	>>>	7	Strong positive (3+)	15 %

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC2/21 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 14.09.2021

Test	Sample	Group	N	Result	N <sub>rel</sub>	
Slide	(803) Dako c-erbB-2 Onkoprotein	>>>	14	Strong positive (3+)	29 %	
		(804) Ventana PATHWAY anti-HER-2/neu	>>>	23	Strong positive (3+)	48 %
		(999) another manufacturer	>>>	4	Strong positive (3+)	8,3 %
		Total per sample: n = 48		Success: 100 %		
Total success: 100 %						
<b>(612) C2 expression HER-2/neu</b>						
Slide	(802) Dako HercepTest	>>>	3	Negative (0)	6,4 %	
		>	2	Negative (1+)	4,3 %	
			2	Weak positive (2+)	4,3 %	
	(803) Dako c-erbB-2 Onkoprotein	>>>	8	Negative (0)	17 %	
		>	6	Negative (1+)	13 %	
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	21	Negative (0)	45 %	
		>	1	Negative (1+)	2,1 %	
	(999) another manufacturer	>>>	3	Negative (0)	6,4 %	
		>	1	Negative (1+)	2,1 %	
	Total per sample: n = 47		Success: 96 %			
Total success: 96 %						
<b>(613) C3 expression HER-2/neu</b>						
Slide	(802) Dako HercepTest	±	1	Negative (1+)	2,7 %	
		±	5	Strong positive (3+)	14 %	
	(803) Dako c-erbB-2 Onkoprotein	±	3	Negative (0)	8,1 %	
		±	2	Weak positive (2+)	5,4 %	
	(804) Ventana PATHWAY anti-HER-2/neu	±	6	Strong positive (3+)	16 %	
		±	4	Negative (0)	11 %	
		±	3	Weak positive (2+)	8,1 %	
	(999) another manufacturer	±	9	Strong positive (3+)	24 %	
		±	1	Negative (0)	2,7 %	
		±	1	Weak positive (2+)	2,7 %	
	Total per sample: n = 37		Success (only evaluated results): evaluation			
	<b>(616) D1 expression HER-2/neu</b>					
	Slide	(802) Dako HercepTest		3	Negative (1+)	6,3 %
>>>			4	Weak positive (2+)	8,3 %	
(803) Dako c-erbB-2 Onkoprotein			1	Negative (0)	2,1 %	
		>>>	3	Negative (1+)	6,3 %	
(804) Ventana PATHWAY anti-HER-2/neu		>>>	10	Weak positive (2+)	21 %	
		>>>	10	Negative (1+)	21 %	
(999) another manufacturer		>>>	13	Weak positive (2+)	27 %	
			1	Negative (0)	2,1 %	
Total per sample: n = 48		Success: 60 %				
Total success: 60 %						
<b>(617) D2 expression HER-2/neu</b>						
Slide	(802) Dako HercepTest	>>>	5	Negative (1+)	10 %	
			2	Weak positive (2+)	4,2 %	
	(803) Dako c-erbB-2 Onkoprotein	>	1	Negative (0)	2,1 %	
		>>>	10	Negative (1+)	21 %	
	(804) Ventana PATHWAY anti-HER-2/neu		3	Weak positive (2+)	6,3 %	
		>	6	Negative (0)	13 %	
	(999) another manufacturer	>>>	15	Negative (1+)	31 %	
			2	Weak positive (2+)	4,2 %	
	Total per sample: n = 48		Success: 81 %			
	Total success: 81 %					
<b>(618) D3 expression HER-2/neu</b>						
Slide	(802) Dako HercepTest	>>>	4	Negative (0)	8,3 %	
		>	3	Negative (1+)	6,3 %	
	(803) Dako c-erbB-2 Onkoprotein	>>>	4	Negative (0)	8,3 %	
		>	7	Negative (1+)	15 %	
	(804) Ventana PATHWAY anti-HER-2/neu		3	Weak positive (2+)	6,3 %	
		>>>	19	Negative (0)	40 %	
	(999) another manufacturer	>	3	Negative (1+)	6,3 %	
		>>>	1	Strong positive (3+)	2,1 %	
	Total per sample: n = 48		Success: 90 %			

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC2/21 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 14.09.2021

Test	Sample	Group	N	Result	N <sub>rel</sub>
Total success: 90 %					
<b>(621) E1 expression HER-2/neu</b>					
Slide	(802)	Dako HercepTest	>>>	2 Negative (0)	4,2 %
			>	3 Negative (1+)	6,3 %
				2 Weak positive (2+)	4,2 %
	(803)	Dako c-erbB-2 Onkoprotein	>>>	5 Negative (0)	10 %
			>	5 Negative (1+)	10 %
				4 Weak positive (2+)	8,3 %
	(804)	Ventana PATHWAY anti-HER-2/neu	>>>	19 Negative (0)	40 %
			>	4 Negative (1+)	8,3 %
	(999)	another manufacturer	>>>	2 Negative (0)	4,2 %
			>	2 Negative (1+)	4,2 %
Total per sample: n = 48 Success: 88 %					
Total success: 88 %					
<b>(622) E2 expression HER-2/neu</b>					
Slide	(802)	Dako HercepTest	±	6 Negative (0)	19 %
	(803)	Dako c-erbB-2 Onkoprotein	±	9 Negative (0)	29 %
			±	1 Negative (1+)	3,2 %
	(804)	Ventana PATHWAY anti-HER-2/neu	±	12 Negative (0)	39 %
	(999)	another manufacturer	±	3 Negative (0)	9,7 %
Total per sample: n = 31 Success (only evaluated results): evaluation					
<b>(623) E3 expression HER-2/neu</b>					
Slide	(802)	Dako HercepTest	>>>	7 Negative (0)	15 %
	(803)	Dako c-erbB-2 Onkoprotein	>>>	14 Negative (0)	29 %
	(804)	Ventana PATHWAY anti-HER-2/neu	>>>	23 Negative (0)	48 %
	(999)	another manufacturer	>>>	3 Negative (0)	6,3 %
			>	1 Negative (1+)	2,1 %
Total per sample: n = 48 Success: 100 %					
Total success: 100 %					
<b>(651) A1 sample staining</b>					
Slide	(0)	not specified	>>>	48 6 points	100 %
Total per sample: n = 48 Success: 100 %					
Total success: 100 %					
<b>(652) A2 sample staining</b>					
Slide	(0)	not specified	>	12 3 points	25 %
			>>>	36 6 points	75 %
Total per sample: n = 48 Success: 100 %					
Total success: 100 %					
<b>(653) A3 sample staining</b>					
Slide	(0)	not specified	>>>	47 6 points	100 %
Total per sample: n = 47 Success: 100 %					
Total success: 100 %					
<b>(656) B1 sample staining</b>					
Slide	(0)	not specified	±	48 6 points	100 %
Total per sample: n = 48 Success (only evaluated results): evaluation					
<b>(657) B2 sample staining</b>					
Slide	(0)	not specified	>	1 3 points	2,1 %
			>>>	47 6 points	98 %
Total per sample: n = 48 Success: 100 %					
Total success: 100 %					
<b>(658) B3 sample staining</b>					
Slide	(0)	not specified	±	47 6 points	100 %
Total per sample: n = 47 Success (only evaluated results): evaluation					
<b>(661) C1 sample staining</b>					
Slide	(0)	not specified	>	2 3 points	4,2 %
			>>>	46 6 points	96 %
Total per sample: n = 48 Success: 100 %					
Total success: 100 %					
<b>(662) C2 sample staining</b>					
Slide	(0)	not specified	>>>	46 6 points	100 %
Total per sample: n = 46 Success: 100 %					
Total success: 100 %					
<b>(663) C3 sample staining</b>					
Slide	(0)	not specified	±	48 6 points	100 %

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC2/21 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 14.09.2021

Test		N	Result	N <sub>rel</sub>
Total per sample: n = 48		Success (only evaluated results): evaluation		
<b>(666) D1 sample staining</b>				
Slide	(0) not specified	15	0 points	31 %
		>	21 3 points	44 %
		>>>	1 5 points	2,1 %
		>>>	11 6 points	23 %
Total per sample: n = 48		Success: 69 %		
Total success: 69 %				
<b>(667) D2 sample staining</b>				
Slide	(0) not specified	>	1 3 points	2,1 %
		>>>	47 6 points	98 %
Total per sample: n = 48		Success: 100 %		
Total success: 100 %				
<b>(668) D3 sample staining</b>				
Slide	(0) not specified	>	1 3 points	2,1 %
		>>>	47 6 points	98 %
Total per sample: n = 48		Success: 100 %		
Total success: 100 %				
<b>(671) E1 sample staining</b>				
Slide	(0) not specified	>>>	48 6 points	100 %
Total per sample: n = 48		Success: 100 %		
Total success: 100 %				
<b>(672) E2 sample staining</b>				
Slide	(0) not specified	±	48 6 points	100 %
Total per sample: n = 48		Success (only evaluated results): evaluation		
<b>(673) E3 sample staining</b>				
Slide	(0) not specified	>>>	48 6 points	100 %
Total per sample: n = 48		Success: 100 %		
Total success: 100 %				
<b>(681) IQC</b>				
Slide	(0) not specified	4	0 points	8,3 %
		>	24 3 points	50 %
		>>>	20 6 points	42 %
Total per sample: n = 48		Success: 92 %		
Total success: 92 %				

st\_kl

End of report

Printed: 30.09.2021